RU99107670A - Высокопродуктивная экспрессия белков - Google Patents
Высокопродуктивная экспрессия белковInfo
- Publication number
- RU99107670A RU99107670A RU99107670/13A RU99107670A RU99107670A RU 99107670 A RU99107670 A RU 99107670A RU 99107670/13 A RU99107670/13 A RU 99107670/13A RU 99107670 A RU99107670 A RU 99107670A RU 99107670 A RU99107670 A RU 99107670A
- Authority
- RU
- Russia
- Prior art keywords
- gene
- synthetic gene
- preferred
- protein
- synthetic
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims 9
- 108090000623 proteins and genes Proteins 0.000 title claims 9
- 108020004705 Codon Proteins 0.000 claims 8
- 238000000338 in vitro Methods 0.000 claims 6
- 238000004113 cell culture Methods 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 102000001690 Factor VIII Human genes 0.000 claims 3
- 108010054218 Factor VIII Proteins 0.000 claims 3
- 210000004962 mammalian cells Anatomy 0.000 claims 3
- 229920001405 Coding region Polymers 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
Claims (19)
1. Синтетический ген, кодирующий зеленый флуоресцентный белок, в котором, как минимум, один непредпочтительный или менее предпочтительный кодон природного гена, кодирующего указанный белок, был заменен предпочтительным кодоном, кодирующим ту же аминокислоту, отличающийся тем, что указанный синтетический ген способен экспрессировать указанный белок на уровне, который, как минимум, составляет 110% от уровня экспрессии указанного природного гена в in vitro культуральной системе клеток млекопитающего в идентичных условиях.
2. Синтетический ген, кодирующий белок Фактор VIII, не содержащий центрального домена В-области, в котором, как минимум, один непредпочтительный или менее предпочтительный кодон природного гена, кодирующем указанный белок, был заменен предпочтительным кодоном, кодирующим ту же аминокислоту, отличающийся тем, что указанный синтетический ген обладает способностью экспрессировать указанный белок на уровне, который, как минимум, составляет 110% от уровня экспрессии указанного природного гена в in vitro культуральной системе клеток млекопитающего в идентичных условиях.
3. Синтетический ген по п.1 или 2, в котором указанный синтетический ген способен экспрессировать указанный белок на уровне, который составляет, как минимум, 150% от уровня экспрессии указанного природного гена в in vitro клеточной культуральной системе в идентичных условиях.
4. Синтетический ген по п.1 или 2, в котором указанный синтетический ген способен экспрессировать указанный белок на уровне, который составляет, как минимум, 200% от уровня экспрессии указанного природного гена в in vitro клеточной культуральной системе в идентичных условиях.
5. Синтетический ген по п.1 или 2, в котором указанный синтетический ген способен экспрессировать указанный белок на уровне, который составляет, как минимум, 500% от уровня экспрессии указанного природного гена в in vitro клеточной культуральной системе в идентичных условиях.
6. Синтетический ген по п.1 или 2, в котором указанный синтетический ген способен экспрессировать указанный белок на уровне, который составляет, как минимум, 1000% от уровня экспрессии указанного природного гена в in vitro клеточной культуральной системе в идентичных условиях.
7. Синтетический ген по п.1 или 2, в котором указанный синтетический ген содержит менее 5 встречаемых последовательностей CG.
8. Синтетический ген по п.1 или 2, в котором, как минимум, 10% кодонов в указанном природном гене представляют собой непредпочтительные кодоны.
9. Синтетический ген по п.1 или 2, в котором, как минимум, 50% кодонов в указанном природном гене представляют собой непредпочтительные кодоны.
10. Синтетический ген по п.1 или 2, в котором, как минимум, 50% непредпочтительных кодонов и менее предпочтительных кодонов, представленных в указанном природном гене, были заменены предпочтительными кодонами.
11. Синтетический ген по п.1 или 2, в котором, как минимум, 90% непредпочтительных кодонов и менее предпочтительных кодонов, представленных в указанном природном гене, были заменены предпочтительными кодонами.
12. Синтетический ген по п.1 или 2, в котором 20% кодонов представляют собой предпочтительные кодоны.
13. Синтетический ген по п.1, в котором указанный ген обладает кодирующей последовательностью, представленной в SEQ ID NO : 40.
14. Синтетический ген по п.2, в котором указанный ген обладает кодирующей последовательностью, представленной в SEQ ID NO : 42.
15. Экспрессионный вектор, включающий синтетический ген по п.1 или 2.
16. Экспрессионный вектор по п.15, отличающийся тем, что указанный экспрессионный вектор представляет собой экспрессионный вектор млекопитающего.
17. Клетка млекопитающего, несущая синтетический ген по п.1 или 2.
18. Способ получения синтетического зеленого флуоресцентного гена, включающий определение непредпочтительных и менее предпочтительных кодонов в природном гене зеленого флуоресцентного белка и замену одного или нескольких непредпочтительных или менее предпочтительных кодонов предпочтительным кодоном, кодирующим ту же аминокислоту, что и замещаемый кодон.
19. Способ получения синтетического гена, кодирующего белок Фактор VIII, не содержащий в центральный домен В-области, включающий определение непредпочтительных и менее предпочтительных кодонов в природном гене, кодирующем указанный белок Фактор VIII, не содержащий центральный домен В-области, и замену одного или нескольких указанных непредпочтительных и менее предпочтительных кодонов предпочтительным кодоном, кодирующим ту же аминокислоту, что и замещаемый кодон.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/717,294 | 1996-09-20 | ||
US08717294 US6114148C1 (en) | 1996-09-20 | 1996-09-20 | High level expression of proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99107670A true RU99107670A (ru) | 2001-03-10 |
RU2233329C2 RU2233329C2 (ru) | 2004-07-27 |
Family
ID=24881447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU99107670/13A RU2233329C2 (ru) | 1996-09-20 | 1997-09-18 | Синтетический ген, кодирующий зеленый флуоресцентный белок, способ получения гена, экспрессирующий вектор, способ получения культуры клеток |
Country Status (19)
Country | Link |
---|---|
US (1) | US6114148C1 (ru) |
EP (1) | EP0929564B1 (ru) |
JP (1) | JP2001503252A (ru) |
KR (1) | KR100490321B1 (ru) |
CN (1) | CN1307195C (ru) |
AT (1) | ATE389666T1 (ru) |
AU (1) | AU737122B2 (ru) |
BR (1) | BR9712077A (ru) |
CA (1) | CA2265976C (ru) |
CZ (1) | CZ96899A3 (ru) |
DE (1) | DE69738586T2 (ru) |
DK (1) | DK0929564T3 (ru) |
ES (1) | ES2304791T3 (ru) |
HU (1) | HUP9904239A3 (ru) |
MX (1) | MX259447B (ru) |
PL (2) | PL191300B1 (ru) |
RU (1) | RU2233329C2 (ru) |
TR (1) | TR199900624T2 (ru) |
WO (1) | WO1998012207A1 (ru) |
Families Citing this family (254)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5786464C1 (en) * | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
US6534312B1 (en) | 1996-02-22 | 2003-03-18 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
IL131131A0 (en) * | 1997-02-07 | 2001-01-28 | Merck & Co Inc | Synthetic hiv gag genes |
US6696291B2 (en) * | 1997-02-07 | 2004-02-24 | Merck & Co., Inc. | Synthetic HIV gag genes |
WO1999002694A1 (en) * | 1997-07-09 | 1999-01-21 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
AUPP807899A0 (en) * | 1999-01-08 | 1999-02-04 | University Of Queensland, The | Codon utilization |
US6602677B1 (en) * | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
OA11520A (en) | 1997-10-20 | 2004-02-09 | Genzyme Transgenics Corp | Novel modified MSP-1 nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems. |
GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
GB9810752D0 (en) * | 1998-05-19 | 1998-07-15 | Glaxo Group Ltd | Cystosine deaminase gene |
US6958226B1 (en) | 1998-09-11 | 2005-10-25 | The Children's Medical Center Corp. | Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins |
AU6139699A (en) * | 1998-09-11 | 2000-04-03 | Children's Medical Center Corporation | Packaging cell lines for hiv-derived retroviral vector particles |
US20090017533A1 (en) * | 1998-09-29 | 2009-01-15 | Shire Human Genetic Therapies, Inc., A Delaware Corporation | Optimized messenger rna |
US6924365B1 (en) | 1998-09-29 | 2005-08-02 | Transkaryotic Therapies, Inc. | Optimized messenger RNA |
US20050037335A1 (en) * | 1998-11-07 | 2005-02-17 | Wolfgang Hillen | Method for identifying novel transcriptional regulatory proteins |
ES2299276T3 (es) | 1998-12-31 | 2008-05-16 | Novartis Vaccines And Diagnostics, Inc. | Polipeptidos env del vih modificados. |
US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
JP2003523721A (ja) * | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
CA2360347C (en) * | 1998-12-31 | 2013-05-07 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
AUPP807799A0 (en) * | 1999-01-08 | 1999-02-04 | University Of Queensland, The | Polynucleotide and method |
CA2369119A1 (en) | 1999-03-29 | 2000-05-25 | Statens Serum Institut | Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope |
RU2001131728A (ru) * | 1999-04-26 | 2004-02-20 | К.Ю. Левен Рисерч Энд Дивелопмент (Be) | Синтетический ген для экспрессии активного ретровирусного белка в эукариотах |
US20050271689A1 (en) * | 2003-07-11 | 2005-12-08 | Chun-Ming Huang | Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax |
WO2000075347A2 (en) * | 1999-06-07 | 2000-12-14 | Wolfgang Hillen | Tet repressor-based transcriptional regulatory proteins |
WO2002064799A2 (en) * | 1999-09-28 | 2002-08-22 | Transkaryotic Therapies, Inc. | Optimized messenger rna |
EP2275559A3 (en) | 1999-09-28 | 2011-03-23 | Shire Human Genetic Therapies, Inc. | Optimized messenger RNA |
US20030190644A1 (en) | 1999-10-13 | 2003-10-09 | Andreas Braun | Methods for generating databases and databases for identifying polymorphic genetic markers |
US20030096778A1 (en) * | 2002-06-13 | 2003-05-22 | Shiver John W | Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef |
US20040063653A1 (en) * | 2000-12-21 | 2004-04-01 | Shiver John W. | Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol |
US6656706B2 (en) * | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
EP1157404A1 (en) * | 1999-12-24 | 2001-11-28 | Koninklijke Philips Electronics N.V. | A color cathode ray tube comprising a tension mask |
US6502774B1 (en) * | 2000-03-08 | 2003-01-07 | J + L Fiber Services, Inc. | Refiner disk sensor and sensor refiner disk |
EP1136553A1 (en) * | 2000-03-22 | 2001-09-26 | Octagene GmbH | Production of recombinant blood clotting factors in human cell lines |
MXPA02009221A (es) * | 2000-03-22 | 2005-07-25 | Octagene Gmbh | Produccion de factores de coagulacion sanguineo recombinantes en lineas celular humanas. |
GB0017990D0 (en) * | 2000-07-21 | 2000-09-13 | Glaxo Group Ltd | Papilloma virus sequences |
US7879540B1 (en) | 2000-08-24 | 2011-02-01 | Promega Corporation | Synthetic nucleic acid molecule compositions and methods of preparation |
US20030157643A1 (en) * | 2000-08-24 | 2003-08-21 | Almond Brian D | Synthetic nucleic acids from aquatic species |
DE10055545A1 (de) * | 2000-11-09 | 2002-07-25 | Deutsches Krebsforsch | Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen |
DK1857122T3 (da) | 2001-06-05 | 2011-03-21 | Curevac Gmbh | Stabiliseret mRNA med forøget G/C-indhold, kodende for et viralt antigen |
AU2002310438B2 (en) | 2001-06-14 | 2008-05-01 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
EP2280074A3 (en) * | 2001-07-05 | 2011-06-22 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
EP1427806A4 (en) * | 2001-08-31 | 2006-04-26 | Chiron Corp | ANTIGENIC HIV-TYPE B POLYPEPTIDE-CODING POLYNUCLEOTIDES, POLYPEPTIDES, AND USES THEREOF |
US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
US6911538B2 (en) * | 2002-01-16 | 2005-06-28 | Washington University | Engineered open reading frame for p53 |
US7316925B2 (en) * | 2002-07-16 | 2008-01-08 | Vgx Pharmaceuticals, Inc. | Codon optimized synthetic plasmids |
CA2499221A1 (en) * | 2002-09-16 | 2004-03-25 | Promega Corporation | Rapidly degraded reporter fusion proteins |
US20060292566A1 (en) * | 2002-11-08 | 2006-12-28 | The University Of Queensland | Method for optimising gene expressing using synonymous codon optimisation |
US20070073048A1 (en) * | 2003-05-15 | 2007-03-29 | Ying Lian | Hiv polynucleotides and polypeptides derived from botswana mj4 |
GB0325379D0 (en) * | 2003-10-30 | 2003-12-03 | Oxford Biomedica Ltd | Vectors |
EP1685240B1 (en) * | 2003-11-20 | 2014-12-31 | The Board of Trustees of the Leland Stanford Junior University | Improved methods of in vitro protein synthesis |
US20050112551A1 (en) * | 2003-11-24 | 2005-05-26 | Agouron Pharmaceuticals, Inc. | Dual assay for evaluating activity and cytotoxicity of compounds in the same population of cells |
NZ583974A (en) | 2004-05-18 | 2011-11-25 | Intrexon Corp | Methods for dynamic vector assembly of DNA cloning vector plasmids |
US20080044853A1 (en) * | 2004-06-21 | 2008-02-21 | Novozymes A/S | Stably Maintained Multiple Copies of at Least Two Orf in the Same Orientation |
WO2006011966A1 (en) * | 2004-06-30 | 2006-02-02 | Allergan, Inc. | Optimizing expression of active botulinum toxin type e |
CA2575994A1 (en) * | 2004-08-04 | 2006-02-16 | Allergan, Inc. | Optimizing expression of active botulinum toxin type a |
US7728118B2 (en) * | 2004-09-17 | 2010-06-01 | Promega Corporation | Synthetic nucleic acid molecule compositions and methods of preparation |
AU2005295351A1 (en) * | 2004-10-18 | 2006-04-27 | Codon Devices, Inc. | Methods for assembly of high fidelity synthetic polynucleotides |
US20060194214A1 (en) * | 2005-02-28 | 2006-08-31 | George Church | Methods for assembly of high fidelity synthetic polynucleotides |
US20070122817A1 (en) * | 2005-02-28 | 2007-05-31 | George Church | Methods for assembly of high fidelity synthetic polynucleotides |
US7846720B2 (en) * | 2005-01-26 | 2010-12-07 | Vgx Pharmaceuticals, Inc. | Optimized high yield synthetic plasmids |
WO2007042169A2 (en) | 2005-10-07 | 2007-04-19 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Matrix metalloproteinase 11 vaccine |
US20090313708A1 (en) * | 2005-10-14 | 2009-12-17 | Liaw Chen W | Gpr22 and methods relating thereto |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
KR101383476B1 (ko) | 2007-11-01 | 2014-04-11 | 아스테라스 세이야쿠 가부시키가이샤 | 면역억제 폴리펩티드 및 핵산 |
US7561973B1 (en) | 2008-07-31 | 2009-07-14 | Dna Twopointo, Inc. | Methods for determining properties that affect an expression property value of polynucleotides in an expression system |
US8126653B2 (en) * | 2008-07-31 | 2012-02-28 | Dna Twopointo, Inc. | Synthetic nucleic acids for expression of encoded proteins |
US8401798B2 (en) * | 2008-06-06 | 2013-03-19 | Dna Twopointo, Inc. | Systems and methods for constructing frequency lookup tables for expression systems |
US7561972B1 (en) | 2008-06-06 | 2009-07-14 | Dna Twopointo, Inc. | Synthetic nucleic acids for expression of encoded proteins |
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
HRP20220796T1 (hr) | 2010-10-01 | 2022-10-14 | ModernaTX, Inc. | Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe |
DE102010056289A1 (de) | 2010-12-24 | 2012-06-28 | Geneart Ag | Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken |
PT2665818T (pt) | 2011-01-17 | 2017-07-05 | Philip Morris Products Sa | Expressão de proteínas em plantas |
EP2665817A1 (en) | 2011-01-17 | 2013-11-27 | Philip Morris Products S.a.s. | Vectors for nucleic acid expression in plants |
US10183069B2 (en) | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
PL2721153T3 (pl) | 2011-06-16 | 2020-03-31 | The Regents Of The University Of California | Syntetyczne klastry genów |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2013049227A2 (en) | 2011-09-26 | 2013-04-04 | Geneart Ag | High efficiency, small volume nucleic acid synthesis |
EP3492109B1 (en) | 2011-10-03 | 2020-03-04 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
PL2771031T3 (pl) | 2011-10-28 | 2018-09-28 | Prothena Biosciences Limited Co. | Humanizowane przeciwciała rozpoznające alfa-synukleinę |
RS63244B1 (sr) | 2011-12-16 | 2022-06-30 | Modernatx Inc | Kompozicije modifikovane mrna |
WO2013112945A1 (en) | 2012-01-27 | 2013-08-01 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
WO2013152220A2 (en) | 2012-04-04 | 2013-10-10 | Life Technologies Corporation | Tal-effector assembly platform, customized services, kits and assays |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
US9694050B2 (en) * | 2012-10-21 | 2017-07-04 | University Of Rochester | THY1 (CD90) as a novel therapy to control adipose tissue accumulation |
PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
RU2708032C2 (ru) | 2013-02-20 | 2019-12-03 | Новартис Аг | ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII |
EP2958942B1 (en) | 2013-02-20 | 2020-06-03 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
EP2970453B1 (en) | 2013-03-13 | 2019-12-04 | Prothena Biosciences Limited | Tau immunotherapy |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
WO2015012924A2 (en) | 2013-04-29 | 2015-01-29 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof |
PT2981822T (pt) | 2013-05-06 | 2020-12-07 | Scholar Rock Inc | Composições e métodos para modulação do fator de crescimento |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
WO2015004632A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize iapp |
WO2015004633A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize islet-amyloid polypeptide (iapp) |
SG11201602503TA (en) | 2013-10-03 | 2016-04-28 | Moderna Therapeutics Inc | Polynucleotides encoding low density lipoprotein receptor |
CA2925021A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Ag | Modified rna with decreased immunostimulatory properties |
JP2017501848A (ja) | 2013-11-19 | 2017-01-19 | プロセナ バイオサイエンシーズ リミテッド | 便秘症状からのレビー小体病の免疫療法のモニター |
CN116478927A (zh) | 2013-12-19 | 2023-07-25 | 诺华股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
EP3116911B8 (en) | 2014-03-12 | 2019-10-23 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
TW201623331A (zh) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法 |
CA2938931A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
US10059761B2 (en) | 2014-03-12 | 2018-08-28 | Prothena Biosciences Limited | Anti-Laminin4 antibodies specific for LG4-5 |
EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
SG10202109752XA (en) | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
CA2944402A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
BR112016024644A2 (pt) | 2014-04-23 | 2017-10-10 | Modernatx Inc | vacinas de ácido nucleico |
EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
WO2016014576A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
CA3237630A1 (en) | 2014-08-13 | 2016-02-18 | The Children's Hospital Of Philadelphia | An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders |
RU2724999C2 (ru) | 2014-08-19 | 2020-06-29 | Новартис Аг | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
HUE061672T2 (hu) | 2014-11-12 | 2023-08-28 | Seagen Inc | Glikán-interakcióban lévõ vegyületek és felhasználási módszerek |
EP3229959B1 (en) | 2014-12-09 | 2019-05-15 | Life Technologies Corporation | High efficiency, small volume nucleic acid synthesis |
IL253149B2 (en) | 2014-12-29 | 2023-11-01 | Novartis Ag | Methods for preparing cells expressing a chimeric receptor antigen |
TWI718122B (zh) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
TWI769570B (zh) | 2015-01-28 | 2022-07-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
TWI781507B (zh) | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
DK3280729T3 (da) | 2015-04-08 | 2022-07-25 | Novartis Ag | Cd20-behandlinger, cd22-behandlinger og kombinationsbehandlinger med en cd19-kimær antigenreceptor (car)-udtrykkende celle |
AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
EP3603661A3 (en) | 2015-04-22 | 2020-04-01 | CureVac AG | Rna containing composition for treatment of tumor diseases |
US20180298068A1 (en) | 2015-04-23 | 2018-10-18 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
PT3303583T (pt) | 2015-05-29 | 2020-07-07 | Curevac Ag | Um método para produção e purificação de rna, compreendendendo pelo menos um passo de filtração por fluxo tangencial |
EP3322679A4 (en) | 2015-07-13 | 2019-07-10 | Pivot Bio, Inc. | METHODS AND COMPOSITIONS FOR IMPROVING THE CHARACTERISTICS OF A PLANT |
CN109476722A (zh) | 2015-07-21 | 2019-03-15 | 诺华股份有限公司 | 用于改善免疫细胞的功效和扩张的方法 |
CA2998716A1 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
EP3359664A4 (en) | 2015-10-05 | 2019-03-20 | Massachusetts Institute Of Technology | NITROGEN FIXATION WITH REINFORCED NIF CLUSTERS |
JP7066613B2 (ja) | 2015-11-12 | 2022-05-13 | シージェン インコーポレイテッド | グリカン相互作用化合物および使用方法 |
JP6695426B2 (ja) | 2015-11-13 | 2020-05-20 | バクスアルタ インコーポレイテッド | 組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター |
BR112018009717B1 (pt) | 2015-11-13 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Polinucleotídeo, vetor de vírus adeno-associado, partícula de um vírus adeno-associado, métodos para produzir uma partícula de vírus adeno-associado e para transduzir uma célula hospedeira, e, uso de uma partícula de vírus adeno-associado |
SI3380620T1 (sl) | 2015-11-23 | 2024-09-30 | Novartis Ag | Optimizirani lentivirusni prenosni vektorji in njihove uporabe |
AU2016380262B2 (en) | 2015-12-28 | 2023-02-09 | Novartis Ag | Methods of making chimeric antigen receptor -expressing cells |
WO2017114497A1 (en) | 2015-12-30 | 2017-07-06 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
US20210198368A1 (en) | 2016-01-21 | 2021-07-01 | Novartis Ag | Multispecific molecules targeting cll-1 |
WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
JP2019509737A (ja) | 2016-03-11 | 2019-04-11 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | TGFβ1結合性免疫グロブリンおよびその使用 |
EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
EP4219721A3 (en) | 2016-04-15 | 2023-09-06 | Novartis AG | Compositions and methods for selective protein expression |
CU24538B1 (es) | 2016-05-02 | 2021-08-06 | Prothena Biosciences Ltd | Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7 |
CU24537B1 (es) | 2016-05-02 | 2021-07-02 | Prothena Biosciences Ltd | Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6 |
WO2017191559A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Tau immunotherapy |
EP3467499A4 (en) * | 2016-06-02 | 2020-02-19 | Hoyu Co., Ltd. | EIALLERGIEANTIGEN |
EP3464375A2 (en) | 2016-06-02 | 2019-04-10 | Novartis AG | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2018007922A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
JP7017013B2 (ja) | 2016-07-02 | 2022-02-08 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
JP7016470B2 (ja) | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
AU2017295886C1 (en) | 2016-07-15 | 2024-05-16 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
US20190161542A1 (en) | 2016-08-01 | 2019-05-30 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
TW202340473A (zh) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | 利用嵌合抗原受體之癌症治療 |
WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
MX2019008197A (es) | 2017-01-06 | 2019-09-11 | Scholar Rock Inc | Inhibidores de tgfb1 permisivos del contexto, espicificos de isoformas y uso de los mismos. |
ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
EP3589647A1 (en) | 2017-02-28 | 2020-01-08 | Novartis AG | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
KR102653141B1 (ko) | 2017-03-03 | 2024-04-01 | 씨젠 인크. | 글리칸-상호작용 화합물 및 사용 방법 |
EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
IL270375B1 (en) | 2017-05-02 | 2024-08-01 | Prothena Biosciences Ltd | Antibodies that recognize tau |
CN110945127B (zh) | 2017-05-22 | 2024-07-12 | 武田药品工业株式会社 | 用于血友病b的基因疗法的编码具有增加的表达的重组fix的病毒载体 |
EP3652535A1 (en) | 2017-07-10 | 2020-05-20 | Dana-Farber Cancer Institute, Inc. | Identification and use of cytotoxic t lymphocyte (ctl) antigen-specific target cell killing enhancer agents |
CA3071427A1 (en) | 2017-07-28 | 2019-01-31 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof |
US20200255859A1 (en) | 2017-07-31 | 2020-08-13 | Reflection Biotechnologies Limited | Cellular models of and therapies for ocular diseases |
AU2017434556A1 (en) | 2017-09-28 | 2020-04-09 | F. Hoffmann-La Roche Ag | Dosing regimes for treatment of synucleinopathies |
RU2020116579A (ru) | 2017-10-25 | 2021-11-25 | Новартис Аг | Способы получения клеток, экспрессирующих химерный антигенный рецептор |
CN111587287A (zh) | 2017-10-25 | 2020-08-25 | 皮沃特生物股份有限公司 | 用于改良固氮的工程微生物的方法和组合物 |
WO2019089798A1 (en) | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
US20210189367A1 (en) | 2017-12-11 | 2021-06-24 | Senti Biosciences, Inc. | Inducible Cell Receptors for Cell-Based Therapeutics |
US20210163922A1 (en) | 2018-03-19 | 2021-06-03 | Modernatx, Inc. | Assembly and error reduction of synthetic genes from oligonucleotides |
GB201804701D0 (en) | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
EP3802825A1 (en) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
CN112739668A (zh) | 2018-06-27 | 2021-04-30 | 皮沃特生物股份有限公司 | 包括重构固氮微生物的农业组合物 |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
WO2020014473A1 (en) | 2018-07-11 | 2020-01-16 | Scholar Rock, Inc. | TGFβ1 INHIBITORS AND USE THEREOF |
HRP20212034T1 (hr) | 2018-07-11 | 2022-04-01 | Scholar Rock, Inc. | Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe |
MX2021000347A (es) | 2018-07-11 | 2021-04-19 | Scholar Rock Inc | Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos. |
WO2020018419A1 (en) | 2018-07-16 | 2020-01-23 | Baxalta Incorporated | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
BR112021003305A2 (pt) | 2018-08-31 | 2021-05-25 | Novartis Ag | métodos para produzir células que expressam receptor de antígeno quimérico |
WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
EP3856779A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd22 chimeric antigen receptor (car) therapies |
EP3856782A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
BR112021007765A2 (pt) | 2018-10-23 | 2021-08-03 | Scholar Rock, Inc. | inibidores seletivos de rgmc e uso dos mesmos |
CR20210272A (es) | 2018-11-26 | 2021-07-14 | Forty Seven Inc | Anticuerpos humanizados contra c-kit |
KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
US20220073626A1 (en) | 2019-01-03 | 2022-03-10 | Institut National De La Santé Et De La Recheche Médicale (Inserm) | Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer |
WO2020150375A1 (en) | 2019-01-16 | 2020-07-23 | Baxalta Incorporated | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
MX2021009175A (es) | 2019-01-30 | 2021-09-14 | Scholar Rock Inc | Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos. |
EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN113490528A (zh) | 2019-02-15 | 2021-10-08 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
TW202045207A (zh) | 2019-02-25 | 2020-12-16 | 瑞士商諾華公司 | 用於病毒遞送之介孔二氧化矽顆粒組成物 |
CU20210073A7 (es) | 2019-03-03 | 2022-04-07 | Prothena Biosciences Ltd | Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs |
EP3953455A1 (en) | 2019-04-12 | 2022-02-16 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
EP3769816A1 (en) | 2019-07-25 | 2021-01-27 | Ospedale Pediatrico Bambino Gesù | Car-cd123 vector and uses thereof |
IL293215A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors that bind bcma and cd19 and their uses |
CN114981299A (zh) | 2019-12-12 | 2022-08-30 | 武田药品工业株式会社 | 使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法 |
MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
EP4087659A2 (en) | 2020-01-11 | 2022-11-16 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
EP4087649A1 (en) | 2020-01-11 | 2022-11-16 | Scholar Rock, Inc. | Tgfbeta inhibitors and use thereof |
US20230111593A1 (en) | 2020-02-14 | 2023-04-13 | Novartis Ag | Method of predicting response to chimeric antigen receptor therapy |
IL295604A (en) | 2020-02-27 | 2022-10-01 | Novartis Ag | Methods for producing cells expressing a chimeric antigen receptor |
IL295878A (en) | 2020-02-27 | 2022-10-01 | Novartis Ag | Methods for producing cells expressing a chimeric antigen receptor |
CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
JP2023533458A (ja) | 2020-06-24 | 2023-08-03 | プロシーナ バイオサイエンシーズ リミテッド | ソルチリンを認識する抗体 |
UY39324A (es) | 2020-07-16 | 2022-02-25 | Novartis Ag | Anticuerpos anti-betacelulina, sus fragmentos, moléculas de unión multiespecíficas, casetes de expresión, composiciones y métodos de tratamiento. |
WO2022029080A1 (en) | 2020-08-03 | 2022-02-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy |
EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EP4199960A2 (en) | 2020-08-21 | 2023-06-28 | Novartis AG | Compositions and methods for in vivo generation of car expressing cells |
WO2022104061A1 (en) | 2020-11-13 | 2022-05-19 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
JP2024512567A (ja) | 2021-03-23 | 2024-03-19 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | T細胞リンパ腫の診断および治療方法 |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
US11795207B2 (en) | 2021-03-30 | 2023-10-24 | AAVnerGene Inc. | Modified plasma clotting factor VIII and method of use thereof |
EP4314041A1 (en) | 2021-03-30 | 2024-02-07 | Aavnergene Inc. | Modified plasma clotting factor viii and method of use thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
WO2022214681A1 (en) | 2021-04-09 | 2022-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of anaplastic large cell lymphoma |
CN118056008A (zh) | 2021-04-27 | 2024-05-17 | 诺华股份有限公司 | 病毒载体生产系统 |
EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
WO2022264040A1 (en) | 2021-06-14 | 2022-12-22 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
US20240301073A1 (en) | 2021-07-14 | 2024-09-12 | Scholar Rock, Inc. | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF |
WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
WO2023156587A1 (en) | 2022-02-18 | 2023-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance |
WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
WO2023198648A1 (en) | 2022-04-11 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t-cell malignancies |
WO2023198874A1 (en) | 2022-04-15 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t cell-lymphomas |
AR129136A1 (es) | 2022-04-26 | 2024-07-17 | Novartis Ag | Anticuerpos multiespecíficos que se dirigen a il-13 e il-18 |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
US20230365991A1 (en) | 2022-05-12 | 2023-11-16 | AAVnerGene Inc. | Compositions and methods for recombinant parvovirus production |
WO2023237663A1 (en) | 2022-06-09 | 2023-12-14 | Institut National de la Santé et de la Recherche Médicale | Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells |
WO2024003310A1 (en) | 2022-06-30 | 2024-01-04 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of acute lymphoblastic leukemia |
WO2024018003A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Extracellular vesicles functionalized with an erv syncitin and uses thereof for cargo delivery |
WO2024018046A1 (en) | 2022-07-22 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Garp as a biomarker and biotarget in t-cell malignancies |
WO2024023283A1 (en) | 2022-07-29 | 2024-02-01 | Institut National de la Santé et de la Recherche Médicale | Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas |
WO2024047110A1 (en) | 2022-08-31 | 2024-03-07 | Institut National de la Santé et de la Recherche Médicale | Method to generate more efficient car-t cells |
WO2024050450A1 (en) | 2022-08-31 | 2024-03-07 | Gigamune, Inc. | Engineered enveloped vectors and methods of use thereof |
WO2024052318A1 (en) | 2022-09-06 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies |
WO2024056809A1 (en) | 2022-09-15 | 2024-03-21 | Novartis Ag | Treatment of autoimmune disorders using chimeric antigen receptor therapy |
WO2024079192A1 (en) | 2022-10-12 | 2024-04-18 | Institut National de la Santé et de la Recherche Médicale | Cd81 as a biomarker and biotarget in t-cell malignancies |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
WO2024209036A1 (en) | 2023-04-07 | 2024-10-10 | Institut National de la Santé et de la Recherche Médicale | Generating highly pure glutamatergic neuronal populations using the pro-neural factor ascl1 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4652639A (en) * | 1982-05-06 | 1987-03-24 | Amgen | Manufacture and expression of structural genes |
US5464774A (en) * | 1984-03-05 | 1995-11-07 | The Salk Institute For Biological Studies | Bovine basic fibroblast growth factor |
US5276268A (en) * | 1986-08-23 | 1994-01-04 | Hoechst Aktiengesellschaft | Phosphinothricin-resistance gene, and its use |
US5270171A (en) * | 1987-03-06 | 1993-12-14 | Boris Cercek | Cancer-associated SCM-recognition factor, preparation and method of use |
US5244797B1 (en) * | 1988-01-13 | 1998-08-25 | Life Technologies Inc | Cloned genes encoding reverse transcriptase lacking rnase h activity |
IL89567A0 (en) * | 1988-03-28 | 1989-09-10 | Univ Leland Stanford Junior | Mutated hiv envelope protein |
AP129A (en) * | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US5082767A (en) * | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
US5795737A (en) * | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
US5786464C1 (en) * | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
GB9504446D0 (en) * | 1995-03-06 | 1995-04-26 | Medical Res Council | Improvements in or relating to gene expression |
US5874304A (en) * | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
-
1996
- 1996-09-20 US US08717294 patent/US6114148C1/en not_active Expired - Lifetime
-
1997
- 1997-09-18 AU AU43556/97A patent/AU737122B2/en not_active Ceased
- 1997-09-18 WO PCT/US1997/016639 patent/WO1998012207A1/en active IP Right Grant
- 1997-09-18 EP EP97941703A patent/EP0929564B1/en not_active Expired - Lifetime
- 1997-09-18 RU RU99107670/13A patent/RU2233329C2/ru not_active IP Right Cessation
- 1997-09-18 KR KR19997002414A patent/KR100490321B1/ko not_active IP Right Cessation
- 1997-09-18 CA CA002265976A patent/CA2265976C/en not_active Expired - Fee Related
- 1997-09-18 CN CNB971997136A patent/CN1307195C/zh not_active Expired - Fee Related
- 1997-09-18 DE DE69738586T patent/DE69738586T2/de not_active Expired - Fee Related
- 1997-09-18 CZ CZ99968A patent/CZ96899A3/cs unknown
- 1997-09-18 DK DK97941703T patent/DK0929564T3/da active
- 1997-09-18 PL PL332431A patent/PL191300B1/pl unknown
- 1997-09-18 JP JP51489798A patent/JP2001503252A/ja not_active Ceased
- 1997-09-18 AT AT97941703T patent/ATE389666T1/de not_active IP Right Cessation
- 1997-09-18 PL PL376940A patent/PL192104B1/pl not_active IP Right Cessation
- 1997-09-18 TR TR1999/00624T patent/TR199900624T2/xx unknown
- 1997-09-18 HU HU9904239A patent/HUP9904239A3/hu unknown
- 1997-09-18 MX MX9902661A patent/MX259447B/es active IP Right Grant
- 1997-09-18 BR BR9712077-4A patent/BR9712077A/pt not_active Application Discontinuation
- 1997-09-18 ES ES97941703T patent/ES2304791T3/es not_active Expired - Lifetime
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU99107670A (ru) | Высокопродуктивная экспрессия белков | |
Algrain et al. | Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker. | |
US6114148C1 (en) | High level expression of proteins | |
RU2346951C2 (ru) | Выделенный полипептид, связывающий рецептор zalpha11-лиганда (варианты), кодирующий его полинуклеотид (варианты), вектор экспрессии (варианты) и клетка-хозяин (варианты) | |
RU2009131610A (ru) | Среда для культивирования клеток без белков и без сыворотки | |
ATE46536T1 (de) | Verfahren zur herstellung von reifen proteinen in wirtzellen von wirbeltieren. | |
ATE310015T1 (de) | Hohe expressionsrate des grün-fluoreszierenden proteins | |
HUP0101136A2 (hu) | Fehérjeexpresszió baculovírus-vektort alkalmazó expressziós rendszerben | |
CA2400295A1 (en) | Modified factor viii | |
IL186153A0 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
ATE77104T1 (de) | Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute. | |
ES544868A0 (es) | Procedimiento de obtencion de una proteina de factor estimu-lante de colonias (csf) en primates | |
BG101408A (en) | Analogs of keratinocyte growth factor | |
KR880014110A (ko) | 인체 프로아포지방단백질 a-i의 발현 | |
EP0546110A4 (en) | New insulin-like growth factor binding protein igfbp-5 | |
CA2390049A1 (en) | Control of post-transcriptional gene silencing in plants | |
WO1997022690A3 (en) | SIGNALING INOSITOL POLYPHOSPHATE 5-PHOSPHATASES (SIPs) | |
WO2002010384A1 (fr) | Genes codant des proteines capables de regenerer la luciferine, adn recombine et methode de production de proteines capables de regenerer la luciferine | |
Shapiro et al. | A comparison of the membrane-bound and extracellular cyclic AMP phosphodiesterases of Dictyostelium discoideum | |
Roop et al. | The structure and evolution of intermediate filament genes | |
DE69941789D1 (de) | In vivo-verfahren zur herstellung von proteinen, die nicht-konventionelle aminosäuren enthalten | |
HUP9903959A2 (hu) | Csonkított vérlemezke-aktiváló faktor acetilhidroláz | |
WO2002010383A1 (fr) | Genes codant des proteines capables de regenerer la luciferine, adn recombine et methode de production de proteines capables de regenerer la luciferine | |
ATA435083A (de) | Das polypeptid interleukin-2 kodierendes gen, rekombinante, dieses gen enthaltende dna, diese rekombinante dna aufweisende zellinien und verfahren zur herstellung von interleukin-2 unter verwendung der genannten zellen | |
Cao et al. | Cloning, sequencing and expression of the 67-kDa collagen-binding annexin from chicken growth plate matrix vesicles |